Julie Grant

Julie Grant is a General Partner at Canaan, investing in seed through Series C stage companies across biopharma, healthcare, biotechnology, and digital health. She focuses on the United States, particularly the West Coast including California’s San Francisco Bay Area and Silicon Valley (Menlo Park). She serves on the boards of Synthekine and Nocion Therapeutics, Inc., and has invested in companies such as Day One Biopharmaceuticals, Protagonist Therapeutics, Cellular Research, Dermira, and CytomX. Before serving as a General Partner, she held roles as Partner, Principal, and Associate at Canaan Partners, and was Co‑Founder and Chief Executive Officer and later Chair of the Board of Directors at Day One Biopharmaceuticals. She studied at the Stanford University Graduate School of Business and lives in the San Francisco Bay Area.